Novo Holdings

• Novo Holdings Makes Strategic Growth Investment in HST Pathways (Alongside Bain Capital and Nexxus Holdings)

  June 5, 2026

  Buyer

  Novo Holdings, Bain Capital, Nexxus Holdings

  Target

  HST Pathways

  Industry

  Cloud & SaaS

  Location

  United States

  Type

  Growth capital

  HST Pathways, a provider of cloud-based software purpose-built for ambulatory surgery centers (ASCs), announced a strategic growth investment from Novo Holdings. Novo Holdings joins existing investors Bain Capital and Nexxus Holdings to support HST’s next phase of growth, including accelerating its AI and agentic product roadmap for ASC operations.

• Route 92 Medical Raises $50 Million Growth Financing with Sectoral Asset Management

  April 7, 2026

  Buyer

  Novo Holdings, Sectoral Asset Management, U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, The Vertical Group

  Target

  Route 92 Medical, Inc.

  Industry

  Healthcare Services

  Location

  Utah, United States

  Type

  Growth capital

  Route 92 Medical, a neurovascular medical technology company, announced a $50 million growth financing round. Sectoral Asset Management joined the round alongside lead investor Novo Holdings and returning investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group to accelerate global commercial expansion and further clinical and product development.

• KKR-Led Investor Group Makes Follow-on Investment in Sylvan

  January 22, 2026

  Buyer

  KKR, TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee, Novo Holdings

  Target

  Sylvan

  Industry

  Biotechnology

  Location

  Pennsylvania, United States

  Type

  Growth capital

  KKR has completed an additional investment in Sylvan, a global mushroom spawn and fungal biotechnology company, with participation from TPG NewQuest, Ping'An Capital, China Post Insurance, Schroders Capital, Tsao Pao Chee and a follow-on from Novo Holdings. The funding will support Sylvan’s expansion—increasing production capacity, strengthening R&D, developing new product categories and deeper growth across Asian markets—while KKR remains the company’s majority investor.

• Paratek Pharmaceuticals Acquires Optinose to Expand Specialty Therapies Portfolio

  May 21, 2025

  Buyer

  Paratek Pharmaceuticals, Inc., B-FLEXION Life Sciences, Novo Holdings, Oaktree Capital Management, L.P.

  Target

  Optinose, Inc.

  Industry

  Pharmaceuticals

  Location

  United States

  Type

  Buyout

  Paratek Pharmaceuticals completed the acquisition of Optinose, acquiring all outstanding shares for about $330 million, including assumed debt and contingent value rights (CVRs) tied to XHANCE net revenue milestones. The deal adds XHANCE (fluticasone propionate) to Paratek’s portfolio alongside its flagship antibiotic NUZYRA (omadacycline).

• Novo Holdings Acquires Catalent for $16.5 Billion

  December 18, 2024

  Buyer

  Novo Holdings A/S, Novo Nordisk A/S

  Target

  Catalent, Inc.

  Industry

  Healthcare Services

  Location

  New Jersey, United States

  Type

  Buyout

  Novo Holdings A/S agreed to acquire Catalent, Inc. in an all-cash transaction valued at approximately $16.5 billion ($63.50 per share). The deal was later completed, and Catalent became a private company under Novo Holdings ownership; Novo Nordisk subsequently acquired Catalent’s three fill-finish sites in Italy, Indiana (USA), and Belgium.

• Novo Holdings to Acquire Benchmark Genetics

  November 25, 2024

  Buyer

  Novo Holdings

  Target

  Benchmark Genetics

  Seller

  Benchmark Holdings plc

  Industry

  Biotechnology

  Location

  Norway

  Type

  Buyout

  Novo Holdings agreed to acquire Benchmark Genetics from Benchmark Holdings plc for an enterprise value of up to £260 million. Completion is expected in the first quarter of 2025, subject to shareholder approval and regulatory clearances, with initial consideration of £230 million plus up to £30 million contingent on revenue thresholds.

• Novo Holdings Acquires Majority Stake in Stingray Marine Solutions

  October 10, 2024

  Buyer

  Novo Holdings

  Target

  Stingray Marine Solutions

  Industry

  Agriculture

  Location

  Oslo, Norway

  Type

  Buyout

  Novo Holdings has agreed to acquire a majority stake in Stingray Marine Solutions, an Oslo-based provider of intelligent aquaculture technology that removes sea lice using camera vision, software and laser technology. The investment, made by Novo Holdings’ Planetary Health Investments team, is intended to scale Stingray’s sustainable aquaculture solutions and expand opportunities in data & analytics and precision farming.

• Novo Holdings Leads $50M Series F Extension in Route 92 Medical

  September 23, 2024

  Buyer

  Novo Holdings, U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, The Vertical Group

  Target

  Route 92 Medical

  Industry

  Medical Devices

  Location

  California, United States

  Type

  Growth capital

  Novo Holdings led a $50 million investment in Route 92 Medical as a Series F extension, joining returning investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group. The financing will accelerate global commercialization of Route 92's neurovascular intervention product portfolio and support regulatory authorizations in new geographies; Novo Holdings' Noel Jee will join Route 92's board.

• Novo Holdings Invests £50m in Oxford Nanopore Technologies

  August 1, 2024

  Buyer

  Novo Holdings

  Target

  Oxford Nanopore Technologies

  Industry

  Biotechnology

  Location

  England, United Kingdom

  Type

  Growth capital

  Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.

• Novo Holdings Acquires 25% Stake in Sejet Plant Breeding

  June 27, 2024

  Buyer

  Novo Holdings

  Target

  Sejet Plant Breeding

  Seller

  DLG Group

  Industry

  Agriculture

  Location

  Central Denmark Region, Denmark

  Type

  Growth capital

  Novo Holdings has agreed to acquire a 25% minority stake in Sejet Plant Breeding from DLG Group. The partnership will provide growth capital to scale Sejet’s plant-breeding operations and invest in new genomic and breeding technologies to accelerate development of climate-resilient crop varieties.

• Novo Holdings Invests in AgNext Technologies

  June 25, 2024

  Buyer

  Novo Holdings A/S

  Target

  AgNext Technologies Private Limited

  Industry

  Agriculture

  Location

  India

  Type

  Growth capital

  Novo Holdings led a growth investment in AgNext Technologies Private Limited, an India-based agritech company that develops AI-driven food quality assessment solutions. The funding will support product development, international expansion and scaling of sales to new food segments.

• Novo Holdings Acquires Majority Stake in Single Use Support

  May 15, 2024

  Buyer

  Novo Holdings A/S

  Target

  Single Use Support

  Industry

  Biotechnology

  Location

  Tyrol, Austria

  Type

  Buyout

  Novo Holdings A/S agreed to acquire an approximately 60% controlling stake in Single Use Support, a Kufstein, Austria-based life science tools company specializing in fluid management, single-use consumables and cold-chain solutions for bioprocessing. The two founders will each retain 10% and Danaher will retain 20%; the investment is intended to support Single Use Support's next phase of global growth, particularly expansion into the US and Asia, and is subject to regulatory approvals.

Related Acquisition Pages